Product nameAnti-ADAM12 antibody - Aminoterminal end
See all ADAM12 primary antibodies
DescriptionRabbit polyclonal to ADAM12 - Aminoterminal end
SpecificityThis antibody recognizes latent unprocessed and processed forms of ADAM12, but does not react with other ADAMs.
Tested applicationsSuitable for: Flow Cyt, ICC/IF, WB, IHC-Frmore details
Species reactivityReacts with: Mouse, Rat, Human, Pig
Synthetic peptide corresponding to Human ADAM12 (N terminal).
- Cell lysate from human fetal fibroblasts (treated with TNF alpha).
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferpH: 7.40
Preservative: 0.05% Sodium azide
Constituents: 50% Glycerol, 2.9% Sodium chloride, PBS
Concentration information loading...
PurityImmunogen affinity purified
Purification notesThe antibody has been peptide affinity purified.
Our Abpromise guarantee covers the use of ab39155 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use a concentration of 2 µg/ml. PubMed: 19213876
ab171870 - Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody.
|ICC/IF||Use at an assay dependent concentration.|
|WB||1/1000 - 1/5000. Predicted molecular weight: 100 kDa. A recommended starting concentration for Western blots is 1/1000 when using colorimetric substrates such as BCIP/NBT and 1/5000 for chemiluminescent substrates. EDTA/EGTA treatment of tissues or lysates is required to see latent zymogen.|
|IHC-Fr||Use at an assay dependent concentration. PubMed: 23671573|
FunctionInvolved in skeletal muscle regeneration, specifically at the onset of cell fusion. Also involved in macrophage-derived giant cells (MGC) and osteoclast formation from mononuclear precursors.
Tissue specificityIsoform 1 is expressed in placenta and skeletal, cardiac, and smooth muscle. Isoform 2 seems to be expressed only in placenta or in embryo and fetus. Both forms were expressed in some tumor cells lines. Not detected in brain, lung, liver, kidney or pancreas.
Sequence similaritiesContains 1 disintegrin domain.
Contains 1 EGF-like domain.
Contains 1 peptidase M12B domain.
DomainThe cysteine-rich domain supports cell adhesion through syndecans and triggers signaling events that lead to beta-1 integrin-dependent cell spreading. In carcinomas cells the binding of this domain to syndecans does not allow the integrin-mediated cell spreading.
The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
modificationsThe precursor is cleaved by a furin endopeptidase.
Cellular localizationSecreted and Cell membrane.
- Information by UniProt
- A disintegrin and metalloproteinase domain 12 antibody
- ADA12_HUMAN antibody
- ADAM 12 antibody
Anti-ADAM12 antibody - Aminoterminal end (ab39155) at 1/1000 dilution + Human heart tissue lysate - total protein (ab29431) at 10 µg
Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) (ab65484) at 1/3000 dilution
Predicted band size: 100 kDa
Observed band size: 84 kDa why is the actual band size different from the predicted?
Additional bands at: 117 kDa, 42 kDa, 50 kDa. We are unsure as to the identity of these extra bands.
This product has been referenced in:
- Huang X et al. Adam12 and lnc015192 act as ceRNAs in breast cancer by regulating miR-34a. Oncogene N/A:N/A (2018). Read more (PubMed: 30042416) »
- Jiao T et al. Role of MicroRNA-103a Targeting ADAM10 in Abdominal Aortic Aneurysm. Biomed Res Int 2017:9645874 (2017). WB ; Mouse . Read more (PubMed: 28357407) »